Nutrigenomics-Based Personalized Supplements Market Size & Share 2026-2035

Nutrigenomics-Based Personalized Supplements Market Size

The Nutrigenomics-Based Personalized Supplements Market was valued at USD 1.82 billion in 2025, is estimated at USD 2.12 billion in 2026, is projected to expand at a 14.5% CAGR (2026–2035), and is expected to reach USD 7.16 billion by 2035.

The market combines genetic and multi-omics testing, interpretation platforms, and tailored supplement delivery into a recurring wellness model rather than a one-time retail purchase. Its expansion depends on converting biological data into credible, easy-to-use regimens while maintaining consent, data governance, and formulation quality. The broader precision nutrition category was valued at USD 8.2 billion in 2023 and projected to reach USD 24.6 billion by 2028, indicating the commercial setting in which nutrigenomic offerings compete for premium wellness spending ^{[1]Springer. “Genes &Nutrition.” link.springer.com}.

Nutrigenomics-Based Personalized Supplements Market Trends, Growth Drivers & GMI Forecast Outlook

Falling test-input costs and maturing interpretation platforms are widening access to personalized supplement programs, but commercialization remains contingent on trusted genomic-data practices, practitioner readiness, and claim-compliance pathways. The resulting Market Trends favor integrated subscription models while producing uneven channel and geographic adoption.

Key Drivers

Lower sequencing costs change the unit economics of nutrigenomic programs by allowing operators to offer broader biological profiles without proportionately raising acquisition costs. This expands the commercial role of testing from a standalone kit toward an onboarding layer for higher-value formulation, coaching, and re-testing relationships.

Established consumer supplement expenditure also matters because it reduces the behavioral leap required to adopt a tailored regimen. Programs that translate test outputs into simple replenishment decisions can capture premium demand more effectively than those that present biological insight without a convenient delivery pathway. The P&G agreement to acquire Thorne illustrates strategic interest in premium, science-oriented wellness platforms ^{[4]NutraIngredients. “P&G to acquire Thorne in premium wellness play.” nutr aingredients.com}.

Multi-omics integration further changes the product proposition. Static variant reports can identify predispositions, whereas platforms that combine genomic, microbiome, metabolic, and behavioral inputs can refresh recommendations as the consumer's condition changes. That capability raises the value of interpretation software and favors operators able to connect data ingestion, formulation logic, and subscriber experience.

Key Restraints

Clinical adoption is constrained less by consumer curiosity than by the capacity of practitioners to interpret omics-based results responsibly. Providers need decision support, education, and clearly bounded protocols before they can embed these programs in preventive-care workflows. Until then, clinical distribution will remain valuable but harder to scale than digital acquisition.

Data custody is a separate commercial issue. Consumers are being asked to provide information that is durable, sensitive, and difficult to replace, so consent design, deletion rights, security controls, and transparent data-use policies affect conversion rather than merely compliance. Stronger governance can become a differentiator, but it also raises fixed operating requirements for smaller entrants.

European claim and device rules create further friction because testing, recommendation language, and supplement commercialization can trigger different compliance obligations. Operators must build country-sensitive legal and channel models instead of deploying a single global proposition, delaying retail and pharmacy rollout in markets where clinical credibility could otherwise accelerate adoption ^{[5]Alitudo S. “Personalised Nutrition: Scientific Potential and Regulatory Limitations.” alitudos.hr}.

*Evidence anchors use cited external data; demand implications and forecast conditions represent GMI analysis.*

Nutrigenomics-Based Personalized Supplements Market Segment Analysis

By Type

Personalized Supplement Formulations generated USD 982 million in 2025 and are projected to reach USD 3.91 billion by 2035. This segment sits at the revenue center of the Nutrigenomics-Based Personalized Supplements Market because it turns an initial biological assessment into a recurring delivery relationship. Tailored vitamin, mineral, probiotic, fatty-acid, amino-acid, and specialty-nutraceutical regimens can be adjusted around an individual profile, creating a commercial model with greater continuity than standalone test sales.

Genetic Testing Kits &Reagents generated USD 510 million in 2025 and are expected to represent 22.2% of market revenue in 2035. Testing remains the entry point for many programs, covering saliva collection, blood-based collection, SNP panels, and sequencing-enabled inputs. Over time, the segment's role shifts toward efficient data capture as bundled models allocate more of the consumer relationship to interpretation and personalized formulation.

Bioinformatics &AI Interpretation Platforms held an 18.0% share in 2025 and are forecast to reach USD 1.65 billion by 2035. The platform layer converts complex biological inputs into recommendations that consumers, clinicians, and retailers can act on. Its strategic importance rises as operators move beyond static reports toward dynamic engines that incorporate adherence, biomarkers, and changing lifestyle signals into updated formulation logic.

By Personalization Approach

DNA/Genomic Testing held a 52.0% share in 2025 and is projected to account for 40.0% in 2035. DNA-based programs remain the most accessible route to personalized supplementation because genetic information provides a durable baseline for nutrient-metabolism, absorption, and predisposition insights. The expected share moderation reflects the addition of complementary data sources rather than a loss of relevance for genomic testing.

Microbiome Analysis is projected to reach USD 1.86 billion by 2035 and expand at an 18.7% CAGR (2026–2035). Microbiome-led personalization addresses dynamic factors such as digestive function, inflammatory response, and nutrient utilization. Its commercial appeal rests on the need for periodic reassessment, which can support ongoing engagement and differentiate it from genetic testing that typically needs to be completed only once.

Multi-Omics Integration is anticipated to grow at a 22.5% CAGR (2026–2035) and represented 14.0% of market revenue in 2025. This approach combines genomics with microbiome, metabolomic, and, in some cases, wearable-derived information. The richer profile supports more responsive recommendation systems, but it also raises requirements for data integration, laboratory quality, interpretation validation, and consumer communication.

Lifestyle/Phenotypic Data Integration accounted for 12.0% of market revenue in 2025 and is expected to retain a 12.0% share in 2035. Lifestyle and phenotypic inputs provide contextual signals around diet, activity, sleep, biomarkers, and adherence. Their stable position reflects a practical middle ground for consumers seeking more individualized guidance without committing to the broader testing cadence associated with multi-omics programs.

By Application

Obesity/Weight Management generated USD 364 million in 2025 and is forecast to grow at a 15.1% CAGR (2026–2035). The application draws on genetic and phenotypic insights related to appetite, lipid metabolism, insulin sensitivity, and nutrient sufficiency. Its relevance is strengthened where consumers need nutritional support alongside calorie restriction, behavior change, or medically supervised weight-management pathways.

General Wellness/Longevity is expected to expand at a 19.0% CAGR (2026–2035) and reach USD 1.21 billion by 2035. Longevity-oriented programs align with consumer interest in preventive health, biological age, energy, recovery, and healthspan. These offerings can sustain premium positioning when they connect complex biological indicators with specific, comprehensible routines rather than broad wellness claims.

Cardiovascular Health generated USD 291 million in 2025 and is projected to represent 14.0% of market revenue in 2035. Cardiovascular personalization can target nutrition-related pathways involving lipid metabolism, methylation, inflammatory response, and micronutrient needs. The application is well suited to practitioner-mediated settings, where evidence boundaries and individual risk context can be addressed alongside a tailored supplement regimen.

Sports Nutrition/Performance is forecast to reach USD 1.07 billion by 2035 and advance at a 16.5% CAGR (2026–2035). Performance users value recommendations tied to recovery, endurance adaptation, caffeine response, and training nutrition. The segment benefits from both direct consumer demand and institutional settings such as athletic programs, performance clinics, and employer wellness initiatives.

Cognitive/Brain Health is projected to grow at an 18.4% CAGR (2026–2035) and held a 12.0% share in 2025. Cognitive-health offerings use personalization to address consumer concerns around focus, cognitive aging, stress response, and nutritional support for neurological wellness. The category's differentiation depends on avoiding generalized nootropic positioning and demonstrating a credible link between input data, interpretation, and formulation choice.

By Distribution Channel

DTC Online/E-Commerce held a 52.0% share in 2025 and is projected to account for 45.0% in 2035. DTC remains the primary channel for digital consent, test-kit fulfillment, onboarding, and subscription management. Its declining share is consistent with market maturation, as clinical, pharmacy, and telehealth routes gain importance rather than as a sign that online acquisition loses its foundational role.

Healthcare Practitioner/Clinical generated USD 437 million in 2025 and is expected to grow at a 15.3% CAGR (2026–2035). Clinical delivery adds professional interpretation and can support higher-trust, higher-intent relationships. The channel's economics depend on whether operators can reduce the time and training burden placed on practitioners while preserving evidence-based treatment boundaries.

Pharmacies/Health Retail is forecast to reach USD 1.57 billion by 2035 and grow at a 20.6% CAGR (2026–2035). Pharmacy and health retail offer a bridge between digital assessment and in-person product access. Their growth potential depends on compliant recommendation frameworks, pharmacist confidence, and store formats that can support consultation, kit distribution, and replenishment without oversimplifying genetic or multi-omics outputs.

Others (Corporate Wellness, Telehealth) are projected to represent 11.0% of market revenue in 2035 and expand at a 20.6% CAGR (2026–2035). Corporate wellness and telehealth models can lower subscriber-acquisition friction by embedding personalized nutrition within an existing health-service relationship. These channels are particularly relevant for employers, specialty clinics, and virtual-care providers that can connect results review with an ongoing wellness program.

Nutrigenomics-Based Personalized Supplements Market Regional Analysis

North America Nutrigenomics-Based Personalized Supplements Market Analysis

North America held a 44.4% share of the Nutrigenomics-Based Personalized Supplements Market in 2025 and is projected to account for 37.5% in 2035. The region remains commercially mature because it combines extensive DTC health familiarity, established supplement spending, a dense base of platform developers, and growing practitioner participation. Its anticipated share moderation reflects faster development elsewhere rather than a weakening of its underlying consumer and channel infrastructure.

United States

The United States generated USD 703 million in 2025 and is forecast to reach USD 2.32 billion by 2035. The U.S. market benefits from a long-established DTC genetic-testing culture and a broad ecosystem of functional medicine, integrative care, and digital-health providers. These conditions make it a leading test bed for subscription programs that combine home collection, online interpretation, and clinical escalation where needed.

Canada

Canada generated USD 105 million in 2025 and is projected to reach USD 355 million by 2035. Canadian adoption is supported by access to North American digital-health offerings and an expanding practitioner base interested in preventive nutrition. Market development depends on building local clinical confidence and aligning personalized offerings with the country's health-product and privacy expectations.

Europe Nutrigenomics-Based Personalized Supplements Market Analysis

Europe is forecast to grow at a 16.3% CAGR (2026–2035) and reach USD 1.81 billion by 2035. European demand is supported by well-developed nutraceutical markets, preventive-care interest, and pharmacy-led consumer health channels. However, commercialization is more compliance-intensive than in North America, requiring market-specific approaches to health claims, genetic testing, data protection, and practitioner involvement.

Germany

Germany generated USD 107 million in 2025 and is forecast to reach USD 405 million by 2035. Germany's laboratory infrastructure, preventive-health orientation, and pharmacy network support personalized nutrition adoption. The market's ability to translate interest into broader retail access will depend on regulatory clarity and the quality of clinical evidence available to pharmacists and practitioners.

United Kingdom

The United Kingdom accounted for 21.0% of European revenue in 2025 and is forecast to grow at a 16.5% CAGR (2026–2035). The UK combines a digitally engaged consumer base with an active health-technology and personalized-nutrition ecosystem. Its market is positioned to support both DTC experimentation and practitioner-led models, particularly where operators can convert strong consumer interest into sustained evidence-led subscriptions.

Asia Pacific Nutrigenomics-Based Personalized Supplements Market Analysis

Asia Pacific is forecast to grow at a 20.2% CAGR (2026–2035) and reach USD 2.09 billion by 2035. The region's expansion is underpinned by rising health expenditure, digital commerce adoption, greater availability of genomics infrastructure, and a large base of consumers seeking preventive wellness tools. Its markets vary sharply in maturity, with scale opportunities in China and India alongside more clinically oriented models in Japan and South Korea.

China

China generated USD 135 million in 2025 and is projected to reach USD 790 million by 2035. China offers a large consumer base accustomed to mobile-first health services and e-commerce fulfillment. Growth will depend on the ability of operators to establish trusted testing pathways, localize recommendations, and integrate personalized nutrition into the country's rapidly developing digital-health ecosystem.

India

India is projected to grow at a 22.8% CAGR (2026–2035) from USD 70 million in 2025. India's opportunity is linked to urban preventive-health spending, a digitally connected consumer population, and increasingly accessible testing services. The market's pace will be shaped by laboratory-network development, professional confidence in nutrigenomics, and the affordability of programs for the expanding middle-income population.

Japan

Japan held a 20.1% share of Asia Pacific revenue in 2025 and is projected to account for 14.4% in 2035. Japan's personalized-nutrition market is comparatively clinical in orientation, with consumer expectations shaped by preventive medicine and quality standards. This supports premium program positioning and retention, although it can make scale-up more measured than in DTC-first markets.

South Korea

South Korea is projected to reach USD 215 million by 2035 and expand at an 18.2% CAGR (2026–2035). South Korea's advanced biotechnology capabilities, digitally fluent consumers, and strong interest in preventive and appearance-related wellness create favorable conditions for personalized programs. Operators can use the country's connected-health ecosystem to combine high-service digital delivery with clinical and aesthetic-care touchpoints.

Latin America Nutrigenomics-Based Personalized Supplements Market Analysis

Latin America generated USD 98 million in 2025 and is forecast to reach USD 375 million by 2035. Regional demand is concentrated in larger urban consumer markets where supplement use, digital commerce, and preventive-health awareness are strongest. Broader uptake remains sensitive to disposable income, regulatory consistency, and the cost of delivering premium subscription programs beyond major metropolitan areas.

Brazil

Brazil accounted for 44.9% of Latin American revenue in 2025 and is forecast to generate USD 165 million by 2035. Brazil leads the region through its sizable urban consumer base, active supplement industry, and growing DTC health engagement. The country provides a logical regional platform for programs that can pair accessible testing with localized digital education and fulfillment.

Mexico

Mexico is projected to represent 31.5% of Latin American revenue in 2035 and grow at a 16.5% CAGR (2026–2035). Mexico benefits from proximity to U.S. operators, cross-border health-product familiarity, and rising digital-health use in large cities. Spanish-language onboarding, local logistics, and confidence in data handling will be important determinants of conversion and repeat participation.

Middle East & Africa Nutrigenomics-Based Personalized Supplements Market Analysis

The Middle East & Africa held a 2.7% share in 2025 and is forecast to advance at a 16.6% CAGR (2026–2035). Growth is concentrated in higher-income Gulf markets with expanding precision-health and digital-health investment. The region's opportunity is strongest where clinics, wellness providers, and public health initiatives can introduce personalized nutrition within established preventive-care and premium-consumer settings.

Saudi Arabia

Saudi Arabia held a 34.0% share of Middle East & Africa revenue in 2025 and is projected to generate USD 72 million by 2035. National health-transformation priorities and growing preventive-care infrastructure support interest in genomic and personalized-health offerings. The market is particularly relevant for clinically positioned nutrition programs addressing metabolic-health needs through practitioner and corporate-wellness channels.

UAE

The UAE is expected to grow at a 17.8% CAGR (2026–2035) and held a 32.0% share of Middle East & Africa revenue in 2025. The UAE's concentration of high-income consumers, medical-wellness providers, and digital-health activity supports premium program launches. Its clinics and wellness centers can act as trusted introduction points for consumers who want guidance alongside genomic or other biological assessments.

Nutrigenomics-Based Personalized Supplements Market Share & Competitive Landscape

The Nutrigenomics-Based Personalized Supplements Market share remains fragmented, with the top five companies collectively holding 17.5% of global revenue in 2025. Fragmentation reflects the coexistence of genomics specialists, clinical laboratories, subscription formulators, microbiome platforms, and consumer-health brands. Competitive advantage is therefore determined by the depth of proprietary data, interpretation capability, clinical validation, formulation quality, and distribution reach rather than by scale alone.

Thorne HealthTech held a 5.5% market share in 2025. The company's competitive position is strengthened by its ability to connect supplement expertise with biological testing, interpretation, and practitioner relationships. Its pending acquisition by P&G underscores the strategic value placed on premium, science-led wellness platforms ^{[4]NutraIngredients. “P&G to acquire Thorne in premium wellness play.” nutr aingredients.com}.

Viome Life Sciences held a 4.0% market share in 2025. Its microbiome-centered model differentiates through functional biological analysis and made-to-order formulations, positioning the company around ongoing insight and replenishment rather than a conventional supplements transaction.

Metagenics accounted for a 3.5% market share in 2025. Its clinical and practitioner orientation gives it a differentiated position in evidence-led personalization, where professional recommendations, protocol quality, and healthcare-channel credibility matter as much as direct consumer marketing.

Genova Diagnostics occupies an important infrastructure role through laboratory services and diagnostic inputs used by practitioners developing personalized nutrition plans. Its relevance lies in the clinical testing layer, where accuracy, workflow integration, and interpretive support influence whether nutrigenomic recommendations can be used in care settings.

ZOE competes through a science-led model that integrates microbiome, dietary-response, and personalized nutrition insights. Its position demonstrates the growing value of platforms that build a continuing relationship around behavior and biological feedback rather than relying on a single test result.

Nutrigenomix operates primarily through practitioner licensing and clinical genetic-test programs. This model emphasizes institutional credibility and structured professional use, although it also depends on the willingness and preparedness of practitioners to incorporate nutrigenomics into routine patient engagement.

InsideTracker combines biological-age, blood-biomarker, and DNA-informed recommendations for performance and wellness consumers. The model is aligned with demand for longitudinal personalization, especially among users seeking recommendations that change as their physiological data changes.

GenePlanet, GX Sciences, MyDNA, Persona Nutrition, CircleDNA, SelfDecode, LifeDNA, Rootine, and Toolbox Genomics represent varied routes to market, spanning accessible DTC testing, pharmacy and clinical partnerships, lifestyle-data integration, and subscription-based supplement packs. Their competitive pressure is likely to intensify as testing becomes easier to procure and differentiation shifts to interpretation quality, consumer trust, and channel access.

Recent Industry Developments

In August 2026, P&G entered into a definitive agreement to acquire Thorne HealthTech from L Catterton for USD 3.8 billion ^{[4]NutraIngredients. “P&G to acquire Thorne in premium wellness play.” nutr aingredients.com}. The transaction signals that multinational consumer-health companies view personalized, science-backed supplement platforms as strategically relevant assets rather than niche wellness propositions.

In March 2026, Herbalife acquired Bioniq's personalized supplement business assets in a transaction valued at up to USD 150 million ^{[6]Nikki Hancocks. “Herbalife acquires personalized nutrition firm Bioniq in $150 million deal.” nutr aingredients.com}. The deal gives Herbalife a blood-test-driven personalization capability that can be deployed through its international distribution model, adding momentum to competitive consolidation around data-led nutrition platforms.

In September 2026, TSI Group expanded its Tailored Script precision-personalized supplements platform to the United States and Australia ^{[7]Emily Letton. “TSI Group brings precision personalised supplements to US and Australia.” nutraceuticalbusinessreview.com}. The expansion illustrates continued commercial interest in taking tailored formulation models across multiple developed consumer-health markets.